---
title: "Lysergide (DT120) in Generalized anxiety disorder: Pregabalin"
description: "Formulary evidence on Lysergide (DT120, MM120) in Generalized anxiety disorder: Pregabalin. Topics: FDA-approved indications of pregabalin in the United States, European Union authorization for generalized anxiety disorder, CANMAT guideline: first-line agent and second-line adjunctive therapy, NICE guideline: pregabalin when SSRIs and SNRIs are not tolerated, and 7 further topics. 11 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description/pregabalin"
published: "2026-11-18T10:42:08-05:00"
modified: "2026-11-18T10:42:08-05:00"
---

# Lysergide (DT120) in Generalized anxiety disorder: Pregabalin

<a id="heading-2.2.2.1.4"></a>

## 2.2.2.1.4 Pregabalin

<a id="topic-2.2.2.1.4-1"></a>

### FDA-approved indications of pregabalin in the United States

> “LYRICA is indicated for:”
> “Management of neuropathic pain associated with diabetic peripheral neuropathy”
> “Management of postherpetic neuralgia”
> “Adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older”
> “Management of fibromyalgia”
> “Management of neuropathic pain associated with spinal cord injury”

Source: [Lyrica prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021446s046,022488s022lbl.pdf)

<a id="topic-2.2.2.1.4-2"></a>

### European Union authorization for generalized anxiety disorder

> “Lyrica is indicated for the treatment of Generalised Anxiety Disorder (GAD) in adults.”
> “The dose range is 150 to 600 mg per day given as two or three divided doses. The need for treatment should be reassessed regularly.”
> “Pregabalin has been studied in 6 controlled trials of 4-6 week duration, an elderly study of 8 week duration and a long-term relapse prevention study with a double-blind relapse prevention phase of 6 months duration.”
> “Relief of the symptoms of GAD as reflected by the Hamilton Anxiety Rating Scale (HAM-A) was observed by Week 1.”
> “In controlled clinical trials (4-8 week duration) 52% of the pregabalin treated patients and 38% of the patients on placebo had at least a 50% improvement in HAM-A total score from baseline to endpoint.”

Source: [EMA Lyrica product information (2026)](https://www.ema.europa.eu/en/documents/product-information/lyrica-epar-product-information_en.pdf)

<a id="topic-2.2.2.1.4-3"></a>

### CANMAT guideline: first-line agent and second-line adjunctive therapy

> “The anticonvulsant pregabalin is also a recommended first-line therapy.”
> “Pregabalin: The anticonvulsant pregabalin was more effective than placebo in RCTs”
> “Pregabalin was more effective than venlafaxine XR in one RCT”
> “Second-line adjunctive therapies: Adjunctive pregabalin demonstrated good efficacy in a large RCT in patients with GAD who had an inadequate response to prior treatments (Level 2)”

Source: [Katzman et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4120194/)

<a id="topic-2.2.2.1.4-4"></a>

### NICE guideline: pregabalin when SSRIs and SNRIs are not tolerated

> “If the person cannot tolerate SSRIs or SNRIs, consider offering pregabalin.”
> “As of 1 April 2019, pregabalin is a Class C controlled substance (under the Misuse of Drugs Act 1971) and scheduled under the Misuse of Drugs Regulations 2001 as Schedule 3. Evaluate patients carefully for a history of drug abuse before prescribing and observe patients for development of signs of abuse and dependence (MHRA, Drug Safety Update April 2019).”

Source: [NICE clinical guideline CG113 (2011)](https://www.nice.org.uk/guidance/cg113/chapter/Recommendations)

<a id="topic-2.2.2.1.4-5"></a>

### BAP guideline: alternative initial treatment, augmentation, and adverse effects

> “SNRIs and pregabalin may be considered as alternative initial treatments if SSRIs are judged to be unsuitable”
> “Consider pregabalin augmentation after a non-response to initial SSRI or SNRI treatment”
> “Remember that higher daily doses of pregabalin may be associated with greater response rates”
> “Common adverse effects include drowsiness and dizziness”
> “weight gain in approximately 20% of patients”
> “Discontinuation symptoms after abrupt withdrawal of pregabalin have been reported, as has the abuse of pregabalin generally in individuals with a history of other substance abuse”

Source: [Baldwin et al. (2014)](https://www.bap.org.uk/pdfs/BAP_Guidelines-Anxiety.pdf)

<a id="topic-2.2.2.1.4-6"></a>

### WFSBP guideline: recommended medications and national approval

> “Some of the medications recommended in this guideline may not (or not yet) have received approval for the treatment of anxiety disorders in every country.”

Source: [Bandelow et al. (2023)](https://www.tandfonline.com/doi/full/10.1080/15622975.2022.2086295)

<a id="topic-2.2.2.1.4-7"></a>

### AAFP review: antidepressants before pregabalin

> “Antidepressants should be tried before pregabalin”
> “which appears effective but may cause weight gain and sedation.”

Source: [DeGeorge et al. (2022)](https://www.aafp.org/pubs/afp/issues/2022/0800/generalized-anxiety-disorder-panic-disorder.html)

<a id="topic-2.2.2.1.4-8"></a>

### Network meta-analysis: HAM-A difference from placebo

> “pregabalin (MD -2·79, 95% CrI -3·69 to -1·91)”

Source: [Slee et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30712879/)

<a id="topic-2.2.2.1.4-9"></a>

### Meta-analysis of placebo-controlled trials: effect size and dropout

> “We included eight randomized-controlled trials (n=2299) in our study, comparing the use of PGB in different dosages and placebo.”
> “In terms of the main outcome, PGB was found to be superior to the placebo group (Hedges' g=0.37; 95% confidence interval 0.30-0.44).”
> “No difference between PGB and placebo groups was observed in terms of the dropout rates.”
> “PGB was comparable to benzodiazepines in clinical response, but had lower dropout rates than benzodiazepine.”

Source: [Generoso et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/27643884/)

<a id="topic-2.2.2.1.4-10"></a>

### Onset, weight gain, and abuse liability

> “Pregabalin is reported to be generally well-tolerated in adult patients with GAD and has a rapid onset of action compared to many other pharmacotherapies, approximately one week, as well as comparable efficacy to benzodiazepines”
> “The most significant treatment limiting adverse event appears to be the weight gain associated with pregabalin.”
> “However, pharmacovigilance data suggest that both pregabalin (and gabapentin) have abuse liability and are associated with overdose fatalities”

Source: [Strawn et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6340395/)

<a id="topic-2.2.2.1.4-11"></a>

### Controlled substance schedule, abuse, and dependence: U.S. prescribing information

> “LYRICA is a Schedule V controlled substance.”
> “In controlled clinical studies in over 5500 patients, 4 % of LYRICA-treated patients and 1 % of placebo-treated patients overall reported euphoria as an adverse reaction, though in some patient populations studied, this reporting rate was higher and ranged from 1 to 12%.”
> “In clinical studies, following abrupt or rapid discontinuation of LYRICA, some patients reported symptoms including insomnia, nausea, headache or diarrhea”

Source: [Lyrica prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021446s046,022488s022lbl.pdf)

## Related pages
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Terms and abbreviations](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations.md)
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Product information and disease description](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Clinical evidence](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Economic information and modeling report](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics.md)
- [Lysergide (DT120) in Generalized anxiety disorder: References](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references.md)
